Lipocalin2 as a potential antibacterial drug against Acinetobacter baumannii infection

Cited 1 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorD Lim-
dc.contributor.authorSu-Jin Park-
dc.contributor.authorH Y Kim-
dc.contributor.authorM Shin-
dc.contributor.authorM Song-
dc.date.accessioned2022-03-29T15:31:21Z-
dc.date.available2022-03-29T15:31:21Z-
dc.date.issued2022-
dc.identifier.issn12258873-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/25660-
dc.description.abstractAvailable antibiotics to treat Acinetobacter baumannii infection is limited due to increasing resistance and the emergence of multiple drug-resistant strains. Hence, discovering effective agents against A. baumannii to reduce the number of infection-related deaths is imperative. In search of novel and alternative antibiotics, the antibacterial function of lipocalin2 (Lcn2) was investigated to treat systemic infections of A. baumannii using a mouse neutropenia model. We observed a significant increase in serum Lcn2 levels upon bacterial injection into the mouse, and the administration of recombinant Lcn2 (rmLcn2) extended their survival. Such protective effects were also observed in rmLcn2-pretreated macrophages, where rmLcn2 reduced the survival of the pathogen inside the macrophages. The underlying molecular mechanism of Lcn2 protection was also investigated. We observed that pretreatment of the Raw-264.7 macrophages with rmLcn2 markedly altered the expression of tonB3, which encodes a component of the transporter for ferrisiderophores in A. baumannii. However, the expression of katG, the gene encoding catalase, remained unaffected. These indicate that Lcn2-mediated defense against the pathogen is related to nutritional immunity rather than reactive oxygen species (ROS) production. Furthermore, the addition of rmLcn2 in infected mice diminished bacterial burden in multiple organs and enhanced the expression of tonB3 in the liver, spleen, and lungs of the infected mice. Increased survival rate due to rmLcn2 treatment declined when the infection model was established using lcn2-defective (lcn2-/-) mice, which indicated the necessity of endogenous Lcn2. Therefore, the antibacterial function of Lcn2 can be exploited to develop an alternative therapeutic agent against A. baumannii.-
dc.publisherMicrobiological Society Korea-
dc.titleLipocalin2 as a potential antibacterial drug against Acinetobacter baumannii infection-
dc.title.alternativeLipocalin2 as a potential antibacterial drug against Acinetobacter baumannii infection-
dc.typeArticle-
dc.citation.titleJournal of Microbiology-
dc.citation.number4-
dc.citation.endPage449-
dc.citation.startPage444-
dc.citation.volume60-
dc.contributor.affiliatedAuthorSu-Jin Park-
dc.contributor.alternativeName임대진-
dc.contributor.alternativeName박수진-
dc.contributor.alternativeName김하영-
dc.contributor.alternativeName신민상-
dc.contributor.alternativeName송미령-
dc.identifier.bibliographicCitationJournal of Microbiology, vol. 60, no. 4, pp. 444-449-
dc.identifier.doi10.1007/s12275-022-2007-1-
dc.subject.keywordLlipocalin2-
dc.subject.keywordAcinetobacter baumannii-
dc.subject.keywordInfection-
dc.subject.keywordSepsis-
dc.subject.localLlipocalin2-
dc.subject.localAcinetobacter baumannii-
dc.subject.localInfection-
dc.subject.localinfection-
dc.subject.localSepsis-
dc.subject.localsepsis-
dc.description.journalClassY-
Appears in Collections:
Jeonbuk Branch Institute > Functional Biomaterial Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.